Jazz Pharmaceuticals Plc - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Jazz Pharmaceuticals Plc on February 14, 2019. The report addresses corporate governance changes, specifically the expansion of the Board of Directors and the appointment of a new director.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on director compensation and governance rather than financial performance.
Material Changes
- Board Expansion: The total number of authorized board members was increased from eleven to twelve.
- Director Election: Anne O'Riordan was elected as a Class III director, effective February 14, 2019, with a term expiring at the 2020 annual general meeting.
- Compensation Structure: Ms. O'Riordan will receive an annual cash retainer of $60,000, paid quarterly on a pro-rata basis.
- Equity Awards:
- Initial Grant: A combined grant date value of approximately $600,000, split 50% in stock options and 50% in restricted stock units (RSUs).
- Continuing Annual Grants: Eligible for future annual grants with a combined value of approximately $400,000, split 50% in options and 50% in RSUs.
Outlook, Risks, and Contingencies
The filing does not contain management commentary on business outlook, risks, or contingencies. It notes that Ms. O'Riordan entered into a standard indemnification agreement, requiring the Company to indemnify her against certain expenses incurred due to her position as a director.
Key Facts for Investor Verification
- Verify the vesting schedules for the initial $600,000 equity grant (options vesting over 25 months; RSUs vesting over 3 years).
- Confirm the impact of the new director on board committee assignments and governance policies.
- Review the referenced exhibits (Non-Employee Director Compensation Policy and NEDSAP) for full terms of the equity awards.
- Note that this filing does not impact the company's financial statements for the period ended March 31, 2019, beyond the accrual of the pro-rated cash retainer.